Pure MHC

Pure MHC, LLC is a worldwide leader in the discovery, development, and validation of HLA peptide targets for immunotherapy in cancer, autoimmunity, and infectious disease. Our company’s soluble HLA platform and deep domain expertise in disease-specific HLA Class I and Class II target identification and validation represent a unique set of holistic capabilities in HLA research. Pure MHC, along with its sister company Pure Protein, provide collaborative support to researchers in HLA target validation, development, and therapeutic exploitation through expansive HLA experience and expertise in mass spectrometry, proteomics, informatics, target screening & validation, peptide binding, and HLA extraction from primary tumor and healthy tissues.